Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release

Neuropsychopharmacology

Volumn 25, Issue 2, 2001, Pages 157-164

  Balla, Andrea ^a   Koneru, Rajeth ^a   Smiley, John ^a   Sershen, Henry ^a,b   Javitt, Daniel C ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amphetamine; Dopamine; Glutamate; NMDA receptors; Striatum

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; AMPHETAMINE; DOPAMINE; HOMOVANILLIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFECT; HYPERACTIVITY; LOCOMOTION; MALE; MICRODIALYSIS; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROVOCATION TEST; RAT; SCHIZOPHRENIA;

3,4-DIHYDROXYPHENYLACETIC ACID; AMPHETAMINE; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; DOPAMINE; EXCITATORY AMINO ACID ANTAGONISTS; HOMOVANILLIC ACID; MALE; MOTOR ACTIVITY; PHENCYCLIDINE; PSYCHOMOTOR AGITATION; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA;

EID: 0034988360     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(01)00230-5     Document Type: Article

References (39)

1. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort
2. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
3. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach
4. In vivo modulation of excitatory amino acid receptors: Microdialysis studies on N-methyl-D-aspartate-evoked striatal dopamine release and effects of antagonists
5. Dopamine in schizophrenia: A review and reconceptualization
6. Abnormal mental states induced by phencyclidine as a model of schizophrenia
7. MK-801 increase locomotor activity without elevating extracellular dopamine levels in the nucleus accumbens
8. The modulation of dopaminergic transmission in the striatum by MK-801 is independent of presynaptic mechanisms
9. Regulation of NMDA-stimulated [14C]GABA and [3H]acetylcholine release by striatal glutamate and dopamine receptors
10. Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine
11. Negative schizophrenic symptomatology and the phencyclidine (PCP) model of schizophrenia
12. Non-competitive regulation of phencyclidine/å-receptors by the N-methyl-D-aspartate receptor antagonist D(-)2-amino-5-phosphonovaleric acid
13. Recent advances in the phencyclidine model of schizophrenia
14. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors
15. Inhibition of striatal dopamine release by glycine and glycyldodecylamide
16. Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion
17. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia
18. MK-801 fails to modify the effect of methamphetamine on dopmaine release in the rat striatum
19. Single photon emission computerized tomography imaging of amphetamine- induced dopamine release in drug-free schizophrenic subjects
20. Increased dopamine transmission in schizoprenia: Relationship to illness phases
21. In vivo effects of local and systemic phencyclidine on the extracellular levels of catecholamines and transmitter amino acids in the dorsolateral striatum of anaesthetized rats
22. Behavioral effects of chronic phencyclidine in monkeys
23. Study of a new schizophrenomimetic drug, Sernyl
24. Model psychoses and schizophrenia
25. Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats
26. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis
27. Differential effects of phencyclidine and methamphetamine on dopamine metabolism in rat frontal cortex and striatum as revealed by in vivo dialysis
28. Glutamate receptor dysfunction in schizophrenia
29. Chronic D-amphetamine and phencyclidine: Effects on dopamine agonist and antagonist binding sites in the extrapyramidal and mesolimbic systems
30. Effects of continuous D-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats
31. Phencyclidine in the social interaction test: An animal model of schizophrenia with face and predictive validity
32. Dose-related effects of MK-801 on acute and chronic methylphenidate administration
33. Possible etiology of schizophrenia: Progressive damage to the noradrenergic reward system by 5-hydroxydopamine
34. The delayed effects of phencyclidine enhance amphetamine-induced behavior and striatal C-Fos expression in the rat
35. Quantitation of phencyclidine in serum by enzyme immunoassay: Results in 405 patients
36. Phencyclidine-induced increases in striatal neuron firing in behaving rats: Reversal by haloperidol and clozapine
37. Glutamatergic control over brain dopamine release in vivo and in vitro
38. Potentiation of phencyclidine-induced dopamine release in the rat striatum by the blockade of dopamine D2 receptor